Publications scientifiques

Téléchargez nos documents

2017 Interleukin-7 receptor pathway controls human T cell homing to the gut and predicts response to anti-TNFα therapy in IBD: AAI 2016

2017 Selective targeting of SIRP-alpha induces potent antitumor memory immune responses: AACR 2017

2017 Anti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection: Journal of the American Society of Nephrology

2017 The role of IL-7 in Immunity and Cancer: Anticancer Research

2016 First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28: Journal of immunology

2016 The Present and Future of Inflammatory Bowel Disease Treatment: Advances in IBD

2016 Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors: Expert Opin Biol Ther

2016 Selective targeting of the SIRPα immune checkpoint, but not CD47, controls the polarization of macrophages: EACR 2016

2016 Control of immune tolerance by the SIRPα - CD47 pathway and Myeloid-Derived Suppressor Cells: EACR 2016

2016 Dual targeting of adaptive and innate checkpoints induce potent memory anti-tumor response: EACR 2016

2016 Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling: Cell

2016 Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade: Science

2015 Poster : T-cytotoxic specific immunotherapy in NSCLC with brain metastases: WCLC 2015

2015 Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis: Clinical and experimental Immunology

2015 Presentation : T-cytotoxic specific immunotherapy in NSCLC with brain metastases: WCLC 2015

2015 T cytotoxic specific immunotherapy in NSCLC with brain metastases: WCLC

2015 Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors: Cancer Biol Med

2015 Phase III, randomized trial of nivolumab versus docetaxel in advanced non-squamous cell NSCLC

1 2 3 4